General
Preferred name
CHOLINE SALICYLATE
Synonyms
Salicylic acid, ion(1-), choline ()
Salicylate de choline ()
Choline, salicylate (salt) ()
Salicylic acid choline salt ()
Choline subsalicylate ()
Salicilato de colina ()
Choline salicylic acid salt ()
Dinnefords ()
P&D ID
PD057468
CAS
2016-36-6
Tags
available
drug
Drug indication
Inflammation
Drug Status
nutraceutical
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ABSORPTION Onset: 1-2 hr after ingestion [L2133]; ; In the oral form, choline salicylate is absorbed across the buccal mucosa. There is a need for caution not to exceed the stated dose and monitor for any signs of suggested salicylism, especially when this drug is used for infants [L2135].; ; In one study, it was found that this drug was more rapidly absorbed than ASA (absorption t1/2 = 0.1 vs 0.36 h) [L2138].
PHARMACODYNAMICS This is an anti-inflammatory and antipyretic medication [L2132], [L2133].; ; If is often used in oral gel form for the relief of pain, discomfort, and inflammation caused by common mouth ulcers, cold sores, denture and sore spots, as well as mouth ulcers, and sore spots because of orthodontic devices [L2139].
MOA Choline salicylate relieves pain by inhibition of prostaglandin synthesis and reduces fever by acting on the hypothalamus heat-regulating center. It also inhibits the generation of impulses through the inhibition of cyclooxygenase enzyme (COX) [L2132], [L2136]. ; ; Cyclooxygenase is involved in the production of prostaglandins, in response to injury and after various other stimuli. The prostaglandins promote pain, swelling, and inflammation. The choline salicylate decreases inflammation and pain by reducing the production of these prostaglandins in the area of the mouth it is applied to [L2137].
INDICATION The oral gel is indicated for the relief of pain and discomfort of common mouth ulcers, cold sores, denture sore spots, infant teething and mouth ulcers, and sore spots due to orthodontic devices in children [L2135].; ;
TOXICITY LD50, oral in mouse: 2690mg/kg [L2125]. ; Ld50, subcutaneous in mouse: 1gm/kg [L2125].; ; Interferes with thyroid function test [L2132].; ; Gastrointestinal (GI) disorders, fatigue, hypersensitivity reactions, skin eruptions, hemolytic anemia, weakness, dyspnoea; local irritation (rectally); Reye's syndrome.; ; **Potentially Fatal:** Paroxysmal bronchospasm; hepatotoxicity; renal impairment/failure; thrombocytopenia, iron-deficiency anemia, occult bleeding, leukopenia; mild chronic salicylate intoxication [L2132].; ; Salicylate poisoning is normally associated with plasma concentrations >350 mg/L (2.5 mmol/L). Most adult deaths due to salicylate poisoning occur in patients whose serum concentrations of salicylate are over 700 mg/L (5.1 mmol/L). Single doses of less than 100 mg/kg are very unlikely to lead to serious poisoning. Patients should be provided with supportive therapy or treatment for salicylate poisoning as necessary. This may include treatment like activated charcoal, urinary alkalinization and, in severe cases, hemodialysis [L2139].
METABOLISM The metabolism of salicylic acid is by glycine and phenolic or acyl glucuronate conjugation with small amounts of the drug undergoing hydroxylation [L2139].; ; Extensively metabolized in the liver; inactive metabolites are excreted by the kidneys [L2142].
HALF-LIFE The plasma half-life of salicylic acid is 2-4 hours [L2139].; Up to 15 – 30 h with larger doses due to saturation of liver metabolism capacity [L2142].
Compound Sets
6
ChEMBL Approved Drugs
CHEMBL2104095
ChEMBL Drugs
CHEMBL2104095
DrugBank
DB14006
DrugBank Approved Drugs
DB14006
DrugMAP
DM8P137
DrugMAP Approved Drugs
DM8P137
External IDs
21
Properties
(calculated by RDKit )
Molecular Weight
241.13
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
1
Aromatic Ring Count
1
cLogP
-0.56
TPSA
80.59
Fraction CSP3
0.42
Chiral centers
0.0
Largest ring
6.0
QED
0.7
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Source data